source
- Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trialBiogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…
- Celcuity receives FDA approval for Revtorpyk breast cancer therapyCelcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…